Anatolian Journal of Cardiology最新文献

{"title":"Ultrasound-Assisted Catheter-Directed Thrombolysis vs. Low-Dose Intravenous Tissue-Type Plasminogen Activator Treatments in Acute Intermediate-High Risk Pulmonary Embolism: Insights from a Retrospective Study.","authors":"Cihangir Kaymaz, Barkın Kültürsay, Hacer Ceren Tokgöz, Seda Tanyeri, Berhan Keskin, Çağdaş Buluş, Çağlar Emre Çağlıyan, Deniz Mutlu, Simay Erdal, Faruk Akalın, Rıdvan Bolataslan, Aykun Hakgör, Şeyhmus Külahcıoğlu, İbrahim Halil Tanboğa, Nihal Özdemir","doi":"10.14744/AnatolJCardiol.2026.6510","DOIUrl":"10.14744/AnatolJCardiol.2026.6510","url":null,"abstract":"<p><strong>Background: </strong>Comparative data on ultrasound-assisted catheter-directed thromboly-sis (USAT) and systemic low-dose tissue-type plasminogen activator (tPA) for intermediate-high-risk (IHR) pulmonary embolism (PE) remain limited. The efficacy and safety outcomes of USAT vs. intravenous (IV) low-dose tPA were evaluated in this population.</p><p><strong>Methods: </strong>This study enrolled 329 IHR PE patients treated with USAT (n = 205) or IV low-dose tPA (n = 124). Post-treatment changes in clot burden (Qanadli score), right ventricular (RV) strain, and long-term mortality (median follow-up 95.8 months) were assessed. Propensity score analysis with inverse probability weighting (IPW) was employed to adjust for confounders.</p><p><strong>Results: </strong>Ultrasound-assisted catheter-directed thrombolysis was predominantly bilateral (82.9%), with a mean tPA dose of 38.5 ± 13.6 mg. In the IV tPA cohort, 58.9% required a second infusion to achieve stabilization. While IV tPA was associated with more pronounced early reductions in heart rate and RV/LV (left ventricle) ratio, USAT provided significantly greater thrombus resolution (all P < .005). After IPW adjustment, USAT demonstrated clear superiority over IV tPA in reducing residual clot burden (P < .001). However, improvements in oxygen saturation, tricuspid annular plane systolic excursion , and pulmonary artery systolic pressure (PASP) were comparable. No significant differences were observed in in-hospital mortality, PE recurrence, or long-term survival between cohorts. Higher PE severity indexes scores independently predicted in-hospital adverse events, whereas older age, male sex, and higher discharge PASP were predictors of shortened long-term survival.</p><p><strong>Conclusions: </strong>In IHR PE, IV low-dose tPA relates to more pronounced early hemodynamic and RV diameter improvements, whereas USAT achieves superior thrombus resolution. Despite these divergent surrogate responses, both strategies yield comparable early and long-term clinical outcomes, supporting their roles as viable reperfusion options.</p>","PeriodicalId":7835,"journal":{"name":"Anatolian Journal of Cardiology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148672825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Apolipoprotein E Genotype and Coronary Heart Disease in a Mongolian Cohort: An Exploratory Case-Control Study.","authors":"Ochgerel Dogsom, Ariunzul Punsaldulam, Odonchimeg Dogsom, Tsendsuren Zagdaa, Ganzorig Zundui, Uugantsetseg Ganbat, Oyunchimeg Norovsambuu, Bayarsaikhan Uudus, Narankhajid Myadagsuren, Yeruult Chultemsuren","doi":"10.14744/AnatolJCardiol.2026.6198","DOIUrl":"10.14744/AnatolJCardiol.2026.6198","url":null,"abstract":"<p><strong>Background: </strong>To investigate the association between apolipoprotein E (APOE) gene polymorphisms and coronary heart disease (CHD) risk within a localized Mongolian clinical cohort.</p><p><strong>Methods: </strong>This hospital-based case–control study recruited 63 patients with angiographically confirmed CHD and 61 sex-matched healthy controls. Anthropometric measurements and lipid profiles and pathways for APOE genotypes were strictly assessed. This exploratory hospital-based case–control study was not designed as a nationally representative population-based survey, and participant recruitment was limited to a single tertiary referral center in Mongolia.</p><p><strong>Results: </strong>High-density lipoprotein cholesterol levels were significantly higher in the case group than in the control group (1.56 ± 0.14 vs. 1.33 ± 0.18 mmol/L, P < .001), while total cholesterol was significantly lower in cases than in controls (3.91 ± 0.60 vs. 5.34 ± 0.80 mmol/L, P < .001). The distribution of APOE genotypes (ε2/ε3, ε3/ε3, ε3/ε4, and ε4/ε4) differed significantly between the case and control groups (P = .009). Both systolic and diastolic blood pressure significantly correlated with waist circumference (P = .026). Multivariable logistic regression revealed that the ε2/ε3 genotype was associated with significantly lower odds of disease (odds ratio [OR] = 0.29, P = .007, 95% CI: 0.12-0.71), whereas ε4-related findings were highly imprecise due to sparse genotype counts and lacked statistical significance (OR = 1.07, P = .930, 95% CI: 0.23-5.02).</p><p><strong>Conclusion: </strong>This study showed a significant association between the APOE genotype and CHD in a Mongolian population. These findings highlight the importance of considering qualitative aspects of lipid metabolism, rather than total cholesterol alone, and suggest that genetic factors, including APOE polymorphisms, may contribute to CHD risk independently of absolute cholesterol levels, underscoring the need for population-specific cardiovascular risk assessment.</p>","PeriodicalId":7835,"journal":{"name":"Anatolian Journal of Cardiology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148672692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mixed Reality-Assisted Planning Enables Successful Coil Embolization of Anatomically Complex Peridevice Leak After LAAC.","authors":"Libor Gajdusek, Miroslav Hudec, Otakar Jiravsky, Jaroslav Januska, Jan Hecko, Daniel Precek, Milan Pliva, Daniel Matous, Miloslav Dorda, Jan Chovancik, Vaclav Prochazka","doi":"10.14744/AnatolJCardiol.2026.6165","DOIUrl":"10.14744/AnatolJCardiol.2026.6165","url":null,"abstract":"<p><p></p>","PeriodicalId":7835,"journal":{"name":"Anatolian Journal of Cardiology","volume":"30 8","pages":"543-546"},"PeriodicalIF":2.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13418311/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148629280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacological Insights and Clinical Challenges of Wenxin Keli in Arrhythmia Treatment.","authors":"Jing Fu, Yuanyuan Li, Gaoran Xu, Maochun Li, Yingxiang Chen, Li Xia, Yiwei Ding, Hankun Hu, Yongji Lai","doi":"10.14744/AnatolJCardiol.2026.5694","DOIUrl":"10.14744/AnatolJCardiol.2026.5694","url":null,"abstract":"<p><p>Cardiac arrhythmias remain a leading cause of cardiovascular morbidity and mortality worldwide. Although conventional antiarrhythmic drugs are effective, their use is constrained by proarrhythmic risks and extracardiac toxicity. Wenxin Keli (WXKL), a traditional Chinese medicine (TCM) formula, has demonstrated antiarrhythmic properties in preclinical and clinical studies with a reportedly favorable safety profile. This article provides a critical synthesis of WXKL's pharmacological mechanisms, including ion channel modulation (INa, ICaL, Ito), calcium handling, and calcium/calmodulin-dependent protein kinase II signaling, with explicit appraisal of translational limitations. Clinical trial evidence and meta-analyses for atrial fibrillation (AF), premature ventricular contractions, and other indications were systematically evaluated, with detailed discussion of effect sizes, heterogeneity, and methodological quality. Key challenges unique to WXKL as a TCM-derived product-formulation variability, quality control limitations, and regulatory approval pathways-are analyzed in depth. A prioritized research agenda is proposed to address evidence gaps. *These authors contributed equally to this work and share first authorship.</p>","PeriodicalId":7835,"journal":{"name":"Anatolian Journal of Cardiology","volume":"30 80","pages":"487-500"},"PeriodicalIF":2.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13418305/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148590305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Wenxin Keli, Clopidogrel, Vericiguat and New Impact Factor: 2.1.","authors":"Çetin Erol","doi":"10.14744/AnatolJCardiol.2026.8","DOIUrl":"10.14744/AnatolJCardiol.2026.8","url":null,"abstract":"","PeriodicalId":7835,"journal":{"name":"Anatolian Journal of Cardiology","volume":"30 80","pages":"486"},"PeriodicalIF":2.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13418307/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148590242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic Dysfunction-Associated Steatotic Liver Disease: An Underrated and Emerging Cardiovascular Risk Factor.","authors":"Pierre Sabouret, Domenico Mario Giamundo, Giuseppe Ando, Piera Capranzano, Luigi Spadafora, Stefano Cacciatore, Felice Gragnano, Marco Bernardi, Elad Asher, Michael D Shapiro, Irene Cacciola, Dan Atar, Atul Pathak","doi":"10.14744/AnatolJCardiol.2026.6451","DOIUrl":"10.14744/AnatolJCardiol.2026.6451","url":null,"abstract":"<p><p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide and is increasingly recognized as a major contributor to cardiovascular morbidity and mortality. Beyond liver involvement, MASLD represents a systemic metabolic disorder closely linked to cardiovascular disease (CVD), the leading cause of death in affected patients. This association persists independently of traditional cardiometabolic risk factors and is driven by multiple mechanisms, including insulin resistance, chronic low-grade inflammation, atherogenic dyslipidemia, endothelial dysfunction, and prothrombotic states. Disease severity, particularly liver fibrosis, appears to further increase cardiovascular risk. This review summarizes current evidence on the epidemiological and pathophysiological links between MASLD and CVD, including its role in atherosclerosis, coronary artery disease, and heart failure. Clinical implications for cardiovascular risk stratification, screening, and multidisciplinary management are also discussed, highlighting the need for integrated strategies to reduce both hepatic and cardiovascular complications.</p>","PeriodicalId":7835,"journal":{"name":"Anatolian Journal of Cardiology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13533052/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148590295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Isolated Coronary Sinus Atresia with Unusual Dual Drainage Misdiagnosed as Patent Foramen Ovale: A Case Report with Anatomical Insights.","authors":"Yi Cheng, Jing Li, Xiaojing Ma","doi":"10.14744/AnatolJCardiol.2026.6631","DOIUrl":"10.14744/AnatolJCardiol.2026.6631","url":null,"abstract":"","PeriodicalId":7835,"journal":{"name":"Anatolian Journal of Cardiology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13533045/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148590257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Composite Uric Acid Index for Prediction of Significant Coronary Stenosis on Computed Tomography Angiography.","authors":"Volkan Çamkıran, Gediz Doğay Us, Eray Aksoy, Şahhan Kılıç, Gülsüm Bingöl, Leyla Bulut, Haşim Tüner, Elif Ayduk Gövdeli, Ümit Acar, Batool Achmar, Barış Ökçün, Melih Us","doi":"10.14744/AnatolJCardiol.2026.6279","DOIUrl":"https://doi.org/10.14744/AnatolJCardiol.2026.6279","url":null,"abstract":"<p><strong>Objective: </strong>A recently proposed uric acid index combining fasting glucose, triglycerides, and uric acid has shown promise in cardiovascular risk stratification. It was assessed whether the index could predict significant coronary artery stenosis (≥50%) on coronary computed tomography (CT) angiography and compared its diagnostic performance with serum uric acid.</p><p><strong>Methods: </strong>In this retrospective, single-center study, 258 adults who underwent coronary CT angiography between January 2023 and December 2024 were included. Coronary calcification was scored using the Agatston method by 2 cardiologists. Clinical, demographic, and laboratory data were collected. The uric acid index was calculated as Ln [triglycerides × uric acid × glucose/2]. Univariable and hierarchical multiple logistic regression analyses were performed.</p><p><strong>Results: </strong>Seventy-one patients (27.5%) showed ≥50% stenosis. Those with stenosis were older and had higher Agatston scores, creatinine, uric acid, glucose, HbA1c, and lower high-density lipoprotein cholestrol (HDL-C). In the final multiple models adjusted for age, sex, creatinine and Agatston score, the uric acid index remained a strong independent predictor of ≥50% stenosis (odds ratio [OR] = 1.988, P = .019, 95% confidence interval [CI] = 1.117-3.538). The index demonstrated significant incremental predictive value over the base model, with a Net Reclassification Improvement (NRI) of 0.500 (P < .05) and an Integrated Discrimination Improvement (IDI) of 0.029. The area under the curve for the uric acid index (0.688) exceeded that of uric acid (0.664).</p><p><strong>Conclusion: </strong>In a real-world coronary CT angiography cohort, the composite uric acid index independently predicted significant coronary stenosis. Its incremental predictive value requires validation in larger, prospective studies.</p>","PeriodicalId":7835,"journal":{"name":"Anatolian Journal of Cardiology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148590280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal Assessment of Diastolic Function and Myocardial Strain in Type 2 Diabetes: A Comparison of Empagliflozin and Linagliptin.","authors":"Oğuz Kaan Kaya, Gökhan Köker","doi":"10.14744/AnatolJCardiol.2026.6348","DOIUrl":"https://doi.org/10.14744/AnatolJCardiol.2026.6348","url":null,"abstract":"<p><strong>Objective: </strong>The cardiovascular effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors have attracted increasing interest in patients with type 2 diabetes mellitus. This study aimed to compare the time-dependent effects of empagliflozin and linagliptin on left ventricular diastolic function and global longitudinal strain (GLS).</p><p><strong>Methods: </strong>This prospective longitudinal study included 350 patients with type 2 diabetes mellitus treated with empagliflozin (n = 200) or linagliptin (n = 150). Transthoracic echocardiography and speckle-tracking strain analysis were performed at baseline, 1 month, and 6 months. Diastolic function was evaluated using septal e' velocity, E/e' ratio, isovolumetric relaxation time (IVRT), and mitral E-wave deceleration time. Longitudinal changes were analyzed using linear mixed-effects models including treatment group, time, and group × time interaction.</p><p><strong>Results: </strong>Diastolic function parameters improved significantly over time in both groups (all P < .001). At follow-up, HbA1c levels decreased in both groups, with comparable glycemic control achieved at 6 months. Significant group × time interactions were observed for septal e' velocity, E/e' ratio, and IVRT (all P < .001). These findings remained consistent after adjustment for baseline differences. At 6 months, empagliflozin was associated with greater improvement in septal e' velocity and IVRT, whereas linagliptin resulted in a more pronounced reduction in the E/e' ratio. Although GLS improved in both groups, its temporal pattern differed significantly between treatments (P < .001).</p><p><strong>Conclusion: </strong>Empagliflozin and linagliptin exert distinct effects on left ventricular diastolic function and myocardial deformation in type 2 diabetes mellitus. Empagliflozin appears to provide earlier improvement in diastolic relaxation and GLS, whereas linagliptin may have a greater effect on filling pressures. These findings should be interpreted cautiously and considered hypothesis-generating; confirmation in randomized controlled trials is required to determine their clinical relevance.</p>","PeriodicalId":7835,"journal":{"name":"Anatolian Journal of Cardiology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148590323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TAVI in Patients with Large Aortic Annuli: A Single-Center Experience with Balloon-Expandable Valves.","authors":"Mhd Nawar Alachkar, Cornel Koban, Marc Henning, Grit Tambor, Frank Hölscherman, Anja Haase-Fielitz, Christian Butter","doi":"10.14744/AnatolJCardiol.2026.6548","DOIUrl":"10.14744/AnatolJCardiol.2026.6548","url":null,"abstract":"","PeriodicalId":7835,"journal":{"name":"Anatolian Journal of Cardiology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13533049/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148590272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}